Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
The Chosun Ilbo on MSN
Keytruda Subcutaneous Injection Receives FDA Approval
The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged. Alteogen announced on the 20th that its partner, U.S. Merck, MSD, had ...
Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...
The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely active ulcerative colitis.The approval makes guselkumab (Tremfya, Johnson & ...
Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...
While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is running a separate pivotal study in previously treated Hodgkin lymphoma and ...
The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...
About 60 to 70% of dementia worldwide is accounted for by Alzheimer's disease, and a new era is opening where treatments can be administered at home. On the 29th of last month (local time), Biogen ...
The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...
FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease By Stephanie Brown HealthDay ReporterTUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback